Drug intelligence / Profile preview

TFB-00680

Development stage: Preclinical
Lead developer: ThirtyFiveBio
Modality: Small Molecules
Administration: Oral

Overview

TFB-00680 is a preclinical-stage small molecule agonist of G protein-coupled receptor 35 (GPR35) being developed by ThirtyFiveBio for the treatment of ulcerative colitis. GPR35 is a G protein-coupled receptor that is highly expressed in the intestinal epithelium and immune cells, and genetic variants of the receptor have been strongly associated with an increased risk of inflammatory bowel disease (IBD). By targeting GPR35, TFB-00680 is designed to enhance mucosal barrier function and modulate intestinal inflammation, potentially providing a novel therapeutic approach for patients with ulcerative colitis.

Targets

GPR35 (G-protein Coupled Receptor 35)

Beyond the preview

Go deeper on TFB-00680.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TFB-00680.

Explore the full profile